We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.00 | -1.59% | 124.00 | 124.00 | 125.60 | 124.00 | 124.00 | 124.00 | 4,034 | 08:18:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -15.00 | 840.08M |
TIDMSYNC
RNS Number : 0096M
Syncona Limited
19 May 2022
Syncona Limited
Notice of Final Results
19 May 2022
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, will announce its final results for the year ended 31 March 2022 on Thursday 16 June 2022.
Syncona will host a webcast and conference call the same day at 9.00am BST, with an opportunity to ask questions via the conference call line. The webcast will be available on the Company's website at https://www.synconaltd.com/ or via this link. Alternatively, please contact Syncona@fticonsulting.com for details of the conference call.
[ENDS]
Enquiries
Syncona Ltd
Natalie Garland-Collins / Fergus Witt
Tel: +44 (0) 7714 916615
FTI Consulting
Ben Atwell / Julia Bradshaw / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORBKFBBABKDKPD
(END) Dow Jones Newswires
May 19, 2022 02:02 ET (06:02 GMT)
1 Year Syncona Chart |
1 Month Syncona Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions